Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* AML without complete remission (CR/CRc/CRi) after at least 2 induction therapies OR~* AML that has relapsed within 6 months after obtaining a CR OR~* AML that has relapsed more than 6 months after obtaining a CR, and has treatment failure (TF) or progressive disease (PD) following at least 1 re-induction regimen OR~* AML that has relapsed post Allogeneic transplantation~* Active AML (bone marrow blasts ≥ 5% by morphology, staining, or flow) and/or presence of estramedullary disease~* Available HLA-haploidentical donor that meets the following criteria:~  * Blood-related family member (sibling (full or half), offspring, or parent, cousin, niece or nephew, aunt or uncle, or grandparent)~ * At least 18 years of age~ * HLA-haploidentical donor/recipient match by at least low-resolution typing per institutional standards~ * In the investigator's opinion, is in general good health, and medically able to tolerate leukapheresis required for harvesting HSC~ * No active hepatitis~ * Negative for HTLV and HIV~ * Not pregnant~NOTE: there were HLA-matched sibling and HLA-matched unrelated donor cohorts, but those closed without completion of accrual with Amendment 11~* Karnofsky performance status ≥ 50 %~* Adequate organ function as defined below:~  * Total bilirubin ≤ 2.5 mg/dl (unless the patient has a history of Gilbert's syndrome)~ * AST(SGOT) and ALT(SGPT) ≤ 3.0 x IULN~ * Creatinine ≤ 2.0 x IULN OR estimated creatinine clearance ≥ 30 mL/min/1.73 m2 by Cockcroft-Gault Formula~ * Oxygen saturation ≥ 90% on room air~ * LVEF ≥ 40%~ * FEV1 and FVC ≥ 40% predicted, DLCOc ≥ 40% predicted. If DLCO is \< 40%, patients will still be considered eligible if deemed safe after a pulmonary evaluation.~* At least 18 years of age at the time of study registration~* Able to understand and willing to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable)~Exclusion Criteria:~* Circulating blast count ≥ 10,000/uL by morphology or flow cytometry (cytoreductive therapies including leukapheresis or hydroxyurea are allowed)~* Known HIV or Active hepatitis B or C infection~* Known hypersensitivity to one or more of the study agents~* Currently receiving or has received any investigational drugs within the 14 days prior to the first dose of study drug (Day -7)~* Currently receiving or has received any intensive chemotherapy within the 14 days prior to the first dose of study drug (Day -7) (hydrea or other non-intensive regimens such as decitabine may be used but must stop at least one day prior to the first dose of study drug)~* Pregnant and/or breastfeeding~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmias, or psychiatric illness/social situations that would limit compliance with study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (preparative regimen, transplant, cyclophosphamide) (Type: EXPERIMENTAL): BUSULFAN AND FLUDARABINE BASED PREPARATIVE REGIMEN: Patients receive busulfan IV over 3 hours on days -7 to -4, fludarabine phosphate IV over 30-60 minutes on days -6 to -2, and cyclophosphamide IV over 60 minutes on days -3 and -2.~OR~FLUDARABINE AND TBI BASED PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30-60 minutes on days -6 to -4 and undergo TBI twice daily on days -3 to 0.~AND~DONOR CELL INFUSION: Patients undergo HLA-matched sibling stem cell transplant, HLA-matched unrelated, or HLA-haploidentical transplant on day 0.~AND~POST-TRANSPLANT CYCLOPHOSPHAMIDE: Patients receive cyclophosphamide IV over 90 minutes on days 3 and 4.
- CRS preventive regimen (Type: EXPERIMENTAL): The final \~15 people enrolled who will be recipients of haploidentical transplants will receive tocilizumab IV over 60 minutes 6-12 hours prior to the start of the donor cell infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).